{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:00:48Z","timestamp":1794031248655,"version":"4.8.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The outcome of allogeneic HSCT varies considerably by the disease and remission status at the time of transplantation. Any retrospective or prospective HSCT study that enrolls patients across disease types must account for this heterogeneity; yet, current methods are neither standardized nor validated. We conducted a retrospective study of 1539 patients who underwent transplantation at Dana-Farber Cancer Institute\/Brigham and Women's Hospital from 2000 to 2009. Using multivariable models for overall survival, we created a disease risk index. This tool uses readily available information about disease and disease status to categorize patients into 4 risk groups with significantly different overall survival and progression-free survival on the basis of primarily differences in the relapse risk. This scheme applies regardless of conditioning intensity, is independent of comorbidity index, and was validated in an independent cohort of 672 patients from the Fred Hutchinson Cancer Research Center. This simple and validated scheme could be used to risk-stratify patients in both retrospective and prospective HSCT studies, to calibrate HSCT outcomes across studies and centers, and to promote the design of HSCT clinical trials that enroll patients across diseases and disease states, increasing our ability to study nondisease-specific outcomes in HSCT.<\/jats:p>","DOI":"10.1182\/blood-2012-03-418202","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T03:01:36Z","timestamp":1340074896000},"page":"905-913","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":352,"title":["A disease risk index for patients undergoing allogeneic stem cell transplantation"],"prefix":"10.1182","volume":"120","author":[{"given":"Philippe","family":"Armand","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women's Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed L.","family":"Sorror","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry E.","family":"Storer","sequence":"additional","affiliation":[{"name":"Clinical Statistics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Biostatistics, University of Washington School of Public Health, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2020071612531198800_B1","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1002\/cncr.26033","article-title":"Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.","volume":"117","author":"Juliusson","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"2020071612531198800_B2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1200\/JCO.2010.32.1919","article-title":"Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services.","volume":"29","author":"Giralt","year":"2011","journal-title":"J Clin Oncol"},{"key":"2020071612531198800_B3","first-page":"CD008908","article-title":"Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.","volume":"1","author":"Schlaak","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2020071612531198800_B4","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"issue":"18","key":"2020071612531198800_B5","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2020071612531198800_B6","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2020071612531198800_B7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.","volume":"14","author":"Weisdorf","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020071612531198800_B8","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2020071612531198800_B9","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2020071612531198800_B10","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020071612531198800_B11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbmt.2011.07.024","article-title":"Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.","volume":"18","author":"Armand","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020071612531198800_B12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/bmt.2009.253","article-title":"Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes.","volume":"45","author":"Armand","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2020071612531198800_B13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/0003-4819-144-6-200603210-00007","article-title":"A risk score for mortality after allogeneic hematopoietic cell transplantation.","volume":"144","author":"Parimon","year":"2006","journal-title":"Ann Intern Med"},{"issue":"8","key":"2020071612531198800_B14","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.bbmt.2010.12.702","article-title":"Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.","volume":"17","author":"Ho","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9211","key":"2020071612531198800_B15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(00)02090-0","article-title":"Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial.","volume":"355","author":"Powles","year":"2000","journal-title":"Lancet"},{"issue":"13","key":"2020071612531198800_B16","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study.","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"2020071612531198800_B17","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"446","key":"2020071612531198800_B18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2020071612531198800_B19","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harrell","year":"2001"},{"issue":"4","key":"2020071612531198800_B20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020071612531198800_B21","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2006.06.004","article-title":"Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.","volume":"12","author":"Brown","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020071612531198800_B22","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","article-title":"Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.","volume":"21","author":"Corradini","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"2020071612531198800_B23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2141.2008.07365.x","article-title":"Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.","volume":"143","author":"Rezvani","year":"2008","journal-title":"Br J Haematol"},{"issue":"30","key":"2020071612531198800_B24","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020071612531198800_B25","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome.","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"2020071612531198800_B26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/bmt.2009.253","article-title":"Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes.","volume":"45","author":"Armand","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2020071612531198800_B27","first-page":"S134","article-title":"Autologous versus allogeneic stem cell transplantation in acute myeloid leukemia.","volume":"83","author":"Willemze","year":"2004","journal-title":"Ann Hematol"},{"issue":"7","key":"2020071612531198800_B28","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"issue":"20","key":"2020071612531198800_B29","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"issue":"10","key":"2020071612531198800_B30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","article-title":"Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.","volume":"12","author":"Alyea","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020071612531198800_B31","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2020071612531198800_B32","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2008.02.014","article-title":"Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation.","volume":"14","author":"Tomblyn","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020071612531198800_B33","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/4\/905\/1498787\/zh803012000905.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/4\/905\/1498787\/zh803012000905.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T22:15:27Z","timestamp":1594937727000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/4\/905\/105623\/A-disease-risk-index-for-patients-undergoing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,26]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-418202","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,26]]}}}